Physicians<\/h3>\n \n \n - \n \n \n \n \n \n
![\"](\"https:\/\/www.med.unc.edu\/medicine\/oncology\/wp-content\/uploads\/sites\/1288\/2023\/01\/Abdou-1024x683.jpg\")
\n \n <\/div>\n Yara Abdou, MD <\/a>\n <\/div>\n \t\n <\/div>\n\n \n\n \n\n Assistant Professor of Medicine<\/p>
Breast Cancer Clinical Trial Program Leader<\/p> <\/div>\n \n \n<\/li>
- \n \n \n \n \n \n
![\"](\"https:\/\/www.med.unc.edu\/medicine\/oncology\/wp-content\/uploads\/sites\/1288\/2023\/08\/aldrichjeffrey.jpg\")
\n \n <\/div>\n Jeffrey D. Aldrich, MD <\/a>\n <\/div>\n \t\n <\/div>\n\n \n\n \n\n Assistant Professor of Medicine<\/p> <\/div>\n \n \n<\/li>
- \n \n \n \n \n \n
![\"](\"https:\/\/www.med.unc.edu\/medicine\/oncology\/wp-content\/uploads\/sites\/1288\/2023\/03\/Carey-Lisa-close-up-2023.jpg\")
\n \n <\/div>\n Lisa A. Carey, MD, ScM, FASCO <\/a>\n <\/div>\n \t\n <\/div>\n\n \n\n \n\n L. Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research<\/p>
Deputy Director of Clinical Sciences, Lineberger Comprehensive Cancer Center<\/p> <\/div>\n \n \n<\/li>
- \n \n \n \n \n \n
![\"](\"https:\/\/www.med.unc.edu\/medicine\/oncology\/wp-content\/uploads\/sites\/1288\/2022\/02\/DeesClaire_Division-Photo.jpeg\")
\n \n <\/div>\n E. Claire Dees, MD, ScM <\/a>\n <\/div>\n \t\n <\/div>\n\n \n\n \n\n Professor of Medicine<\/p>
Breast Oncology & Phase I Trials Section Chief<\/p> <\/div>\n \n \n<\/li>
- \n \n \n \n \n \n
![\"](\"https:\/\/www.med.unc.edu\/medicine\/oncology\/wp-content\/uploads\/sites\/1288\/2025\/01\/cropped-Stephen-Kimani-2021-huntsman-headshot.jpg\")
\n \n <\/div>\n Stephen Kimani, MD, MSc <\/a>\n <\/div>\n \t\n <\/div>\n\n \n\n \n\n Assistant Professor of Medicine<\/p> <\/div>\n \n \n<\/li>
- \n \n \n \n \n \n
![\"](\"https:\/\/www.med.unc.edu\/medicine\/oncology\/wp-content\/uploads\/sites\/1288\/2022\/03\/Emily_Ray-768x1024.png\")
\n \n <\/div>\n Emily Ray, MD, MPH <\/a>\n <\/div>\n \t\n <\/div>\n\n \n\n \n\n Associate Professor of Medicine<\/p> <\/div>\n \n \n<\/li>
- \n \n \n \n \n \n
![\"](\"https:\/\/www.med.unc.edu\/medicine\/oncology\/wp-content\/uploads\/sites\/1288\/2023\/03\/reeder-hayes.jpg\")
\n \n <\/div>\n Katherine E. Reeder-Hayes, MD, MBA, MSCR <\/a>\n <\/div>\n \t\n <\/div>\n\n \n\n \n\n Professor of Medicine<\/p>
Breast Cancer Section Chief<\/p> <\/div>\n \n \n<\/li> <\/ul>\n <\/section>\n <\/nav>\n\n \n
Advanced Practice Providers<\/h3>\n \n \n - \n \n \n \n \n
![\"](\"https:\/\/www.med.unc.edu\/medicine\/oncology\/wp-content\/uploads\/sites\/1288\/2022\/05\/Shaunta-Ford-Pierce.png\")
\n \n <\/div>\n Shaunta Ford-Pierce, MSN, FNP-BC, AOCNP <\/div>\n \t\n <\/div>\n\n \n\n \n\n Nurse Practitioner<\/p> <\/div>\n \n \n<\/li>
- \n \n \n \n \n \n
![\"](\"https:\/\/www.med.unc.edu\/medicine\/oncology\/wp-content\/uploads\/sites\/1288\/2022\/02\/judy-gichuhi-763x1024.jpeg\")
\n \n <\/div>\n Judy Gichuhi, MSN, AGNP-C <\/a>\n <\/div>\n \t\n <\/div>\n\n \n\n \n\n Nurse Practitioner<\/p> <\/div>\n \n \n<\/li>
- \n \n \n \n \n \n
![\"](\"https:\/\/www.med.unc.edu\/medicine\/oncology\/wp-content\/uploads\/sites\/1288\/2024\/02\/Meredith-Maguire-683x1024.jpg\")
\n \n <\/div>\n Meredith Maguire, PA <\/a>\n <\/div>\n \t\n <\/div>\n\n \n\n \n\n Physician Assistant<\/p> <\/div>\n \n \n<\/li>
- \n \n \n \n \n \n
![\"](\"https:\/\/www.med.unc.edu\/medicine\/oncology\/wp-content\/uploads\/sites\/1288\/2023\/03\/urbanclarissa.jpg\")
\n \n <\/div>\n Claire Urban, MMSc, PA-C <\/a>\n <\/div>\n \t\n <\/div>\n\n \n\n \n\n Physician Assistant<\/p> <\/div>\n \n \n<\/li> <\/ul>\n <\/section>\n <\/nav>\n\n \n
Nurse Navigators<\/h3>\n \n \n - \n \n \n \n \n
![\"](\"https:\/\/www.med.unc.edu\/medicine\/oncology\/wp-content\/uploads\/sites\/1288\/2022\/05\/Amy-Depue-1024x683.jpg\")
\n \n <\/div>\n Amy Depue, RN, MSN, OCN, CBCN <\/div>\n \t\n <\/div>\n\n \n\n \n\n Nurse Navigator<\/p> <\/div>\n \n \n<\/li>
- \n \n \n \n \n
![\"](\"https:\/\/www.med.unc.edu\/medicine\/oncology\/wp-content\/uploads\/sites\/1288\/2022\/05\/Emily-Riddle.png\")
\n \n <\/div>\n Emily Riddle, RN, BSN, OCN <\/div>\n \t\n <\/div>\n\n \n\n \n\n Nurse Navigator<\/p> <\/div>\n \n \n<\/li> <\/ul>\n <\/section>\n <\/nav>\n\n \n
Clinical Oncology Pharmacist<\/h3>\n \n \n - \n \n \n \n \n
![\"](\"https:\/\/www.med.unc.edu\/medicine\/oncology\/wp-content\/uploads\/sites\/1288\/2022\/05\/Aimee-Faso-1-685x1024.png\")
\n \n <\/div>\n Aimee Faso, PharmD, CPP, BCOP <\/div>\n \t\n <\/div>\n\n \n\n \n\n Oncology Pharmacist<\/p> <\/div>\n \n \n<\/li> <\/ul>\n <\/section>\n <\/nav>\n\n \n
\nWhat Types of Breast Cancer Do We Treat?<\/h2>\n
Our multi-disciplinary team has expertise in the treatment of all breast cancer sub-types, including:<\/p>\n
\n- Hormone Receptor (estrogen and\/or progesterone) positive breast cancer<\/li>\n
- HER2 positive, or over-expressing, breast cancer<\/li>\n
- Triple negative breast cancer<\/li>\n
- Metastatic breast cancer<\/li>\n<\/ul>\n
\nHow We Treat Breast Cancer:<\/h2>\n
Our team attends multiple national and international research meetings each year to stay up to date with the latest innovations in breast cancer care.\u00a0 Following national guidelines and the results of ground-breaking new research as it becomes available, we use a combination of therapies to treat breast cancer, including:<\/p>\n
\n- Endocrine Therapy<\/li>\n
- Chemotherapy<\/li>\n
- Immunotherapy<\/li>\n
- Targeted therapies based on genetic\/genomic testing<\/li>\n
- Clinical trials across the cancer care continuum<\/li>\n
- Survivorship care<\/li>\n<\/ul>\n
\nOur Research & Clinical Trials<\/h2>\n
Our physicians are faculty members of the 黑料网 and include leaders across multiple areas of breast cancer research, including breast cancer genomics with a focus on triple negative disease, drug discovery and early phase clinical research, large clinical trials of new treatments, geriatric oncology, and cancer care delivery research with a focus on improving the equity of breast cancer care.<\/p>\n
A central focus of our research program is the National Cancer Institute-funded Specialized Program of Research Excellence (SPORE) in Breast Cancer.\u00a0 One of only six Breast Cancer SPORE programs in the country, the NCI designation recognizes 黑料网 Breast Care for its efforts to promote collaborative, interdisciplinary and translational cancer research.<\/p>\n
Originally funded in 1992, the 黑料网 SPORE in Breast Cancer has created an outstanding program in translational research. Current focuses of the SPORE program include genetic susceptibility for breast cancer subtypes in Black and White patients, targeting infiltrating immune cells in claudin-low and basal-type tumors, development of new therapeutic targets in triple negative breast cancers, and defining kinome activity for development of novel breast cancer therapies.\u00a0 The SPORE also supports the career development of the next generation of breast cancer researchers.
\n
\nOther Important Services We Offer<\/h2>\n
Our team works closely with experts across the Lineberger Comprehensive Cancer Center to address every aspect of living with breast cancer including:<\/p>\n
\n- Mental healthcare through the Comprehensive Cancer Support Program (CCSP)<\/a><\/li>\n
- Financial counseling and assistance<\/a><\/li>\n
- Nutrition<\/a><\/li>\n
- Social Work<\/a><\/li>\n
- Genetic Counselors<\/a><\/li>\n
- Adolescent and Young Adult Cancer Program<\/a><\/li>\n
- Fertility Preservation\/Counseling<\/a><\/li>\n
- Integrative Medicine<\/a><\/li>\n
- Palliative Care<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"
- \n
- \n \n \n\n \n\n\n \n <\/div>\n Yara Abdou, MD <\/a>\n <\/div>\n \t\n <\/div>\n\n \n\n \n\n
Assistant Professor of Medicine<\/p>
Breast Cancer Clinical Trial Program Leader<\/p> <\/div>\n \n \n<\/li>
- \n
\n \n\n \n\n\n \n <\/div>\n Jeffrey D. Aldrich, MD <\/a>\n <\/div>\n \t\n <\/div>\n\n \n\n \n\nAssistant Professor of Medicine<\/p> <\/div>\n \n \n<\/li>
- \n
\n \n\n \n\n\n \n <\/div>\n Lisa A. Carey, MD, ScM, FASCO <\/a>\n <\/div>\n \t\n <\/div>\n\n \n\n \n\nL. Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research<\/p>
Deputy Director of Clinical Sciences, Lineberger Comprehensive Cancer Center<\/p> <\/div>\n \n \n<\/li>
- \n
\n \n\n \n\n\n \n <\/div>\n E. Claire Dees, MD, ScM <\/a>\n <\/div>\n \t\n <\/div>\n\n \n\n \n\nProfessor of Medicine<\/p>
Breast Oncology & Phase I Trials Section Chief<\/p> <\/div>\n \n \n<\/li>
- \n
\n \n\n \n\n\n \n <\/div>\n Stephen Kimani, MD, MSc <\/a>\n <\/div>\n \t\n <\/div>\n\n \n\n \n\nAssistant Professor of Medicine<\/p> <\/div>\n \n \n<\/li>
- \n
\n \n\n \n\n\n \n <\/div>\n Emily Ray, MD, MPH <\/a>\n <\/div>\n \t\n <\/div>\n\n \n\n \n\nAssociate Professor of Medicine<\/p> <\/div>\n \n \n<\/li>
- \n
\n \n\n \n\n\n \n <\/div>\n Katherine E. Reeder-Hayes, MD, MBA, MSCR <\/a>\n <\/div>\n \t\n <\/div>\n\n \n\n \n\nProfessor of Medicine<\/p>
Breast Cancer Section Chief<\/p> <\/div>\n \n \n<\/li> <\/ul>\n <\/section>\n <\/nav>\n\n \n
Advanced Practice Providers<\/h3>\n
\n - \n
- \n \n \n\n\n\n \n <\/div>\n Shaunta Ford-Pierce, MSN, FNP-BC, AOCNP <\/div>\n \t\n <\/div>\n\n \n\n \n\n
Nurse Practitioner<\/p> <\/div>\n \n \n<\/li>
- \n
\n \n\n \n\n\n \n <\/div>\n Judy Gichuhi, MSN, AGNP-C <\/a>\n <\/div>\n \t\n <\/div>\n\n \n\n \n\nNurse Practitioner<\/p> <\/div>\n \n \n<\/li>
- \n
\n \n\n \n\n\n \n <\/div>\n Meredith Maguire, PA <\/a>\n <\/div>\n \t\n <\/div>\n\n \n\n \n\nPhysician Assistant<\/p> <\/div>\n \n \n<\/li>
- \n
\n \n\n \n\n\n \n <\/div>\n Claire Urban, MMSc, PA-C <\/a>\n <\/div>\n \t\n <\/div>\n\n \n\n \n\nPhysician Assistant<\/p> <\/div>\n \n \n<\/li> <\/ul>\n <\/section>\n <\/nav>\n\n \n
Nurse Navigators<\/h3>\n
\n - \n
- \n \n \n\n\n\n \n <\/div>\n Amy Depue, RN, MSN, OCN, CBCN <\/div>\n \t\n <\/div>\n\n \n\n \n\n
Nurse Navigator<\/p> <\/div>\n \n \n<\/li>
- \n
\n \n\n\n\n \n <\/div>\n Emily Riddle, RN, BSN, OCN <\/div>\n \t\n <\/div>\n\n \n\n \n\nNurse Navigator<\/p> <\/div>\n \n \n<\/li> <\/ul>\n <\/section>\n <\/nav>\n\n \n
Clinical Oncology Pharmacist<\/h3>\n
\n - \n
- \n \n \n\n\n\n \n <\/div>\n Aimee Faso, PharmD, CPP, BCOP <\/div>\n \t\n <\/div>\n\n \n\n \n\n
Oncology Pharmacist<\/p> <\/div>\n \n \n<\/li> <\/ul>\n <\/section>\n <\/nav>\n\n \n
\nWhat Types of Breast Cancer Do We Treat?<\/h2>\n
Our multi-disciplinary team has expertise in the treatment of all breast cancer sub-types, including:<\/p>\n
- \n
- Hormone Receptor (estrogen and\/or progesterone) positive breast cancer<\/li>\n
- HER2 positive, or over-expressing, breast cancer<\/li>\n
- Triple negative breast cancer<\/li>\n
- Metastatic breast cancer<\/li>\n<\/ul>\n
\nHow We Treat Breast Cancer:<\/h2>\n
Our team attends multiple national and international research meetings each year to stay up to date with the latest innovations in breast cancer care.\u00a0 Following national guidelines and the results of ground-breaking new research as it becomes available, we use a combination of therapies to treat breast cancer, including:<\/p>\n
- \n
- Endocrine Therapy<\/li>\n
- Chemotherapy<\/li>\n
- Immunotherapy<\/li>\n
- Targeted therapies based on genetic\/genomic testing<\/li>\n
- Clinical trials across the cancer care continuum<\/li>\n
- Survivorship care<\/li>\n<\/ul>\n
\nOur Research & Clinical Trials<\/h2>\n
Our physicians are faculty members of the 黑料网 and include leaders across multiple areas of breast cancer research, including breast cancer genomics with a focus on triple negative disease, drug discovery and early phase clinical research, large clinical trials of new treatments, geriatric oncology, and cancer care delivery research with a focus on improving the equity of breast cancer care.<\/p>\n
A central focus of our research program is the National Cancer Institute-funded Specialized Program of Research Excellence (SPORE) in Breast Cancer.\u00a0 One of only six Breast Cancer SPORE programs in the country, the NCI designation recognizes 黑料网 Breast Care for its efforts to promote collaborative, interdisciplinary and translational cancer research.<\/p>\n
Originally funded in 1992, the 黑料网 SPORE in Breast Cancer has created an outstanding program in translational research. Current focuses of the SPORE program include genetic susceptibility for breast cancer subtypes in Black and White patients, targeting infiltrating immune cells in claudin-low and basal-type tumors, development of new therapeutic targets in triple negative breast cancers, and defining kinome activity for development of novel breast cancer therapies.\u00a0 The SPORE also supports the career development of the next generation of breast cancer researchers.
\n
\nOther Important Services We Offer<\/h2>\n
Our team works closely with experts across the Lineberger Comprehensive Cancer Center to address every aspect of living with breast cancer including:<\/p>\n
- \n
- Mental healthcare through the Comprehensive Cancer Support Program (CCSP)<\/a><\/li>\n
- Financial counseling and assistance<\/a><\/li>\n
- Nutrition<\/a><\/li>\n
- Social Work<\/a><\/li>\n
- Genetic Counselors<\/a><\/li>\n
- Adolescent and Young Adult Cancer Program<\/a><\/li>\n
- Fertility Preservation\/Counseling<\/a><\/li>\n
- Integrative Medicine<\/a><\/li>\n
- Palliative Care<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"
- Financial counseling and assistance<\/a><\/li>\n
- Mental healthcare through the Comprehensive Cancer Support Program (CCSP)<\/a><\/li>\n
- \n
- \n
- \n